Keytruda heaps pressure on Opdivo with kidney cancer debut by Carly Helfand Monday, April 22, 2019 BMS investors knew trouble would come for Opdivo when Merck’s Keytruda entered the kidney cancer arena, but that trouble arrived two months early.
Keytruda expands lung cancer land grab with another FDA nod by Angus Liu Friday, April 12, 2019 Thanks to a new FDA green light, Keytruda is allowed in patients with low PD-L1 levels, but analysts have expressed doubts about its real-world use.
Nobel winner behind I-O star Opdivo demands a bigger cut by Kyle Blankenship Thursday, April 11, 2019 Opdivo, the Bristol-Myers cancer drug co-developed with Japan’s Ono, is a global cash cow—but a Nobel winner behind the drug isn't happy with his cut.
Loyalty pays: Merck CEO Ken Frazier scores 19% raise by Arlene Weintraub Wednesday, April 10, 2019 Ken Frazier’s total compensation for 2018 was $20.9 million, up from $17.6 million in 2017, enough to put him among the industry's highest paid.
AbbVie, Pfizer lead March pharma TV ad spending by Beth Snyder Bulik Wednesday, April 10, 2019 AbbVie’s Humira and Pfizer’s Xeljanz remained in the top two spots for pharma TV ad spending for the month of March.
Daiichi, Keytruda, Chi-Med and more—FiercePharmaAsia by Angus Liu Friday, April 5, 2019 Daiichi inks $6.9 billion ADC deal with AZ, appoints new CEO; Keytruda nabs first-line lung cancer nod in China.
Merck's Keytruda holds its own in tough lung cancer subgroups by Carly Helfand Monday, April 1, 2019 Last AACR, Merck’s Keytruda-chemo put up stellar lung cancer data. This year, Merck was back to show the combo held up in tough-to-treat patients.
Keytruda spurs long responses in small cell lung cancer by Carly Helfand Monday, April 1, 2019 Merck is awaiting an FDA decision for Keytruda in previously treated small cell lung cancer, and it has new numbers to boost its case.
Keytruda nabs key lung cancer nod in China by Angus Liu Friday, March 29, 2019 Merck's Keytruda has leaped ahead of Bristol-Myers Squibb’s Opdivo and nabbed a green light in newly diagnosed non-small cell lung cancer.
Aducanumab, Keytruda and more—FiercePharmaAsia by Angus Liu Friday, March 22, 2019 Eisai's stock plummets at AD failure; Keytruda has much upside in China, analysts say; Korea Exchange is dragged into Samsung accounting probe.
